The first patient has been enrolled in Svelte Medical System‘s Optimize pivotal trial, which is designed to evaluate the safety and efficacy of Svelte’s drug-eluting stent integrated delivery system and rapid exchange platforms.
The 2,000-person trial comes in the wake of a first-in-man trial for Svelte’s product and a study comparing the system with Medtronic‘s (NYSE:MDT) Resolute Integrity drug-eluting stent. Patients in the feasibility trial finished five-year follow-up with zero reports of clinically-driven major adverse cardiovascular events.
Get the full story at our sister site, Drug Delivery Business News.
The post Svelte Medical launches pivotal trial for drug-eluting stent-on-a-wire appeared first on MassDevice.